EMGALITY (Eli Lilly Australia Pty Ltd)
Product name
EMGALITY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
208 working days (255)
Active ingredients
galcenezumab
Registration type
NCE/NBE
Indication
EMGALITY (solution for injection) is indicated for the prophylaxis of migraine in adults.